European Gastroenterology Therapeutics Market

These are the latest findings from Frost & Sullivan (Palo Alto, CA, USA), an international consulting firm.

The European gastroenterology therapeutics market is in the maturity phase and is highly competitive. Downward price pressures caused by cost control measures implemented by European governments are severely affecting the revenues of market participants. Companies are being forced to reduce the price of their branded products to compete in the market, where generics are heavily recommended, which is severely affecting revenues.

The report found that the gastroenterology therapeutics market in Europe is driven principally by the proton pump inhibitors (PPIs) segment. PPIs, due to their superior efficacy, are replacing the less effective Histamine-2 receptor antagonists and antacids as the primary choice for treating gastroesophageal reflux and peptic ulcer diseases. The lack of innovative therapies in the pipeline implies the continued dominance of PPIs in the market. However, while anti-inflammatory agents and immunosuppressive agents provide relief for patients with inflammatory diseases, questionable side-effect profiles will stimulate the need for improved therapies.

"Poor lifestyles continue to promote the uptake of gastroenterology therapies, and PPI, with its superior efficacy, will help maintain revenue growth,” said Frost & Sullivan research analyst John Paul. "Reference pricing policies implemented by governments are exerting downward pressures on the prices of branded PPIs because of the extensive availability of generic equivalents. Producing innovative products to treat the causes of the diseases is the only solution to prevent decreasing revenues.”

Frost & Sullivan finds that the European gastroenterology therapeutics market was valued at US$10.64 billion in 2006 and estimates this to reach $11.74 billion in 2013.


Related Links:
Frost & Sullivan